Overview

Drug-Drug Interaction of Cladribine and Pantoprazole in Multiple Sclerosis Subjects

Status:
Completed
Trial end date:
2009-01-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to assess the influence of pantoprazole on the pharmacokinetic profile of cladribine, especially in terms of extent of absorption of cladribine since pH-modifying drug may potentially affect the stability of cladribine and thereby its bioavailability
Phase:
Phase 1
Details
Lead Sponsor:
Merck KGaA
Merck KGaA, Darmstadt, Germany
Collaborator:
Merck Serono S.A., Geneva
Treatments:
Cladribine
Pantoprazole